| http://www.w3.org/ns/prov#value | - have symptoms such as fatigue, fever, jaundice and abdominal pain.1 Approximately 60 percent of people who undergo treatment with an initial 48-week regimen of pegylated-interferon and ribavirin, the currently approved medicines for genotype 1 hepatitis C, do not achieve SVR.2,3,4 If treatment is not successful and a person does not achieve SVR, they remain at an increased risk for progressive liv
|
